Suzhou Ribo Life Science Co. Ltd.

This Phase 1 trial tests a single injection of RBD4059, an experimental RNA drug, in healthy adults aged 18 to 65. The drug targets a clotting protein called FXI, which may lower the risk of blood clots with less bleeding risk than standard treatments. Researchers measure safety,…

This study tested an experimental injection called RBD1016 in 48 adults with chronic hepatitis B who were already taking standard antiviral pills. The goal was to see if the injection could safely lower hepatitis B surface antigen (HBsAg), a marker of the virus. Participants rece…